ESCC Molecular Subtypes Based on Multidimensional Features of p53 and Their Clinical Significance

NCT07722819 | Completed

• 2 other identifiers: IRB-2026-482（IIT）2021-40
• Study Type: observational
• Target: 300
• Locations: 1 country
• Sites: 1

Brief Summary

Collect 300 esophageal cancer tissue specimens, including cancer tissue and serum, from a biological sample bank. Collect clinical information on esophageal cancer, including gender, age, time of diagnosis, time of death, treatment information, TNM staging, tumor size, location, etc. DNA sequencing was performed on 300 collected esophageal cancer samples, divided into mutant and wild-type types. Perform immunohistochemistry on tissue slices and observe the expression of P53 mutant protein. ELISA was used to study the expression of serum anti-P53 autoantibodies. Process these data and use them to classify subtypes of esophageal cancer. Associate each subtype with clinical information, analyze the characteristics of each subtype, such as the multidimensional features of P53 and treatment correlation analysis, and the correlation between P53 multidimensional features and survival.

Conditions

P53 Mutation in Esophageal Cancer

Outcome Measures

Primary Outcomes (1)

• Time from surgery to death from any cause (for Overall Survival) or to disease recurrence/local-regional failure (for Recurrence-Free Survival).

  Data collected up to December 31, 2024

Study Arms (1)

Retrospective Cohort

Other: No intervention

Interventions

No intervention OTHER

No intervention

Retrospective Cohort

Eligibility Criteria

• Age: 18 Years - 100 Years
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

This is a single-center, retrospective cohort study. The study population consists of histologically confirmed esophageal squamous cell carcinoma (ESCC) patients who underwent surgical resection at Zhejiang Cancer Hospital between 2015 and 2024. All patients had available p53 molecular data and complete clinical follow-up information.

You may qualify if:

• Histologically confirmed esophageal squamous cell carcinoma (ESCC); Age ≥ 18 years; Undergone surgical resection; Availability of p53 molecular data and clinical follow-up data.

You may not qualify if:

• Incomplete medical records or missing key clinicopathological data. Non-squamous histological types.

Sponsors & Collaborators

• Ling Zhiqiang: lead

Study Sites (1)

Zhejiang Cancer Hospital

Hangzhou, Zhejiang, 310022, China

Location

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Target Duration: 2 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Prof., M.D., PhD,

Study Record Dates

• First Submitted: July 19, 2026
• First Posted: July 23, 2026
• Study Start: April 21, 2026
• Primary Completion: July 13, 2026
• Study Completion: July 13, 2026
• Last Updated: July 23, 2026

Record last verified: 2026-07

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)